Skip to main content

Table 2 Phospho-RTK profiling results for canine primary urothelial carcinoma tumor samples and urothelial carcinoma cell lines

From: Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines

Receptor tyrosine kinase Urothelial carcinoma tumors n (%) Urothelial carcinoma cell lines n (%)
PDGFRa 1 (11%) 1 (25%)
PDGFRb 3 (33%) 1 (25%)
KIT 3 (33%) 1 (25%)
Flt-3 2 (22%) 0 (0%)
M-CSF R 3 (33%) 1 (25%)
VEGFR1 2 (22%) 0 (0%)
VEGFR2 3 (33%) 0 (0%)
VEGFR3 5 (56%) 0 (0%)
EGFR 9 (100%) 4 (100%)
ErbB2 8 (89%) 4 (100%)
ErbB3 3 (33%) 2 (50%)
ErbB4 4 (44%) 1 (25%)
FGFR1 4 (44%) 1 (25%)
FGFR2 4 (44%) 1 (25%)
FGFR3 4 (44%) 1 (25%)
FGFR4 2 (22%) 0 (0%)
Insulin R 7 (78%) 2 (50%)
c-RET 3 (33%) 1 (25%)
ROR1 8 (89%) 4 (100%)
ROR2 8 (89%) 3 (75%)
Tie-1 9 (100%) 4 (100%)
Tie-2 7 (78%) 3 (75%)
  1. The 22 most commonly observed phosphorylated receptor tyrosine kinases on the phospho-RTK Arrays are listed in the first column. The number of primary urothelial carcinoma tumors with the respective phosphorylated RTK is shown as a total and percentage of all tumors (n = 9). The number of primary urothelial carcinoma cell lines with the respective phosphorylated RTK is shown in the right column as a total and percentage of all cell lines (n = 5)